WHODrug: Từ điển Thông tin Dược phẩm Toàn cầu, Đã Được Xác thực và Cập nhật
Tóm tắt
Từ khóa
Tài liệu tham khảo
Lu Z. Technical challenges in designing post-marketing eCRFs to address clinical safety and pharmacovigilance needs. Contemp Clin Trials. 2010;31(1):108–18.
Nair GJ. Ensuring quality in the coding process: a key differentiator for the accurate interpretation of safety data. Perspect Clin Res. 2013;4(3):181–5.
FDA. FDA Data Standards Catalog v5.2 (12-20-2018). In. https://www.fda.gov/industry/fda-resources-data-standards/study-data-standards-resources: FDA.
PMDA. Notification on Practical Operations of Electronic Study Data Submissions In: Bureau PaFS, ed. https://www.pmda.go.jp/english/review-services/reviews/0002.html: PMDA; 2019.
Bejan-Angoulvant T, Genet T, Vrignaud L, Angoulvant D, Fauchier L. Three case reports of involuntary muscular movements as adverse reactions to sacubitril/valsartan. Br J Clin Pharmacol. 2018;84(5):1072–4.
Juhlin K, Karimi G, Andér M, et al. Using VigiBase to identify substandard medicines: detection capacity and key prerequisites. Drug Saf. 2015;38(4):373–82.
van Stekelenborg J, Ellenius J, Maskell S, et al. Recommendations for the use of social media in pharmacovigilance: lessons from IMI WEB-RADR. Drug Saf. 2019;42(12):1393–407.
Ellenius JBT, Dasgupta N, Hedfors S, Pierce C, Norén GN. Medication name entity recognition in tweets using global dictionary lookup and word sense disambiguation. Pharmacoepidemiol Drug Saf. 2016;25(S3):414–5.
Star K, Sandberg L, Bergvall T, Choonara I, Caduff-Janosa P, Edwards IR. Paediatric safety signals identified in VigiBase: methods and results from Uppsala Monitoring Centre. Pharmacoepidemiol Drug Saf. 2019;28(5):680–9.
Wakao R, Taavola H, Sandberg L, et al. Data-driven identification of adverse event reporting patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports. Drug Saf. 2019;42(12):1487–98.
Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res Part C. 2015;105(2):140–56.
The WHO Programme for International Drug Monitoring. 2019; https://www.who.int/medicines/areas/quality_safety/safety_efficacy/National_PV_Centres_Map/en/.
Lindquist M. VigiBase, the WHO Global ICSR Database System: basic Facts. Drug Inf J. 2008;42(5):409–19.
Helling M, Venulet J. Drug recording and classification by the WHO research centre for international monitoring of adverse reactions to drugs. Methods Inf Med. 1974;13(3):169–78.
Venulet J, Borda MH. WHO’s international drug monitoring—the formative years, 1968–1975. Drug Saf. 2010;33(7):e1–23.
FDA US. 21 e-C.F.R. §314:3, 19 December. In: 2019.
WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment, 2019. Oslo, 2018. In:2019.
Watson S, Härmark L. Desogestrel and panic attacks—a new suspected adverse drug reaction reported by patients and health care professionals on spontaneous reports. Br J Clin Pharmacol. 2018;84(8):1858–9.
Heiko Baermann; Matthias Frischmann. Drug Groupings and workflow options for the processing and review of concomitant medication data. PhUSE Annual Conference—Brussels 14th October. 2013.
Rebecca E, Chandler OL. The utilisation of a new tool in signal management—WHODrug Standardised Drug Groupings. ICPE; 2019; Philadelphia.
PMDA. Notification on Practical Operations of Electronic Study Data Submissions In: Bureau PaFS, ed. https://www.pmda.go.jp/english/review-services/reviews/advanced-efforts/0002.html: PMDA; 2015.